tbuckley/cabot-search huggingface dataset:
Erythrocytes as autologous-vaccine carriers targeted in breast cancer sentinel lymph node
Authors: E. Garcia-Giralt, E. M. Lasalvia-Prisco, E. M. Lasalvia-Galante, J. Vázquez, S. Cucchi, G. Spera, J. P. Valentine
Journal: Journal of Clinical Oncology (2008)

14018 Background: In the development of an autologous thermostable hemoderivative cancer vaccine (ATH-CV), an immunotherapeutic site (ITS) was described as the subcutaneous access to the vaccine sentinel lymph node (VSLN). Through ITS, VSLN is reached first by immunomodulatory agents and later by the immunogen ATH-CV. It was demonstrated that immunomodulatory agents GM-CSF and etoposide (ETP) condition VSLN, switching permissive to protective immunity (Disis, 1996; Lasalvia-Prisco, 2007). Continuing the development of this platform, we explored to optimize vaccine immunogen delivery from ITS to the conditioned protective responder VSLN using autologous erythrocytes (AE) as carriers following other demonstrated models (Chiarantini, 1997). In this study we report the results in breast cancer patients. Methods: Immediately after diagnosis, 30 breast cancer patients, stage I-II, with surgery and sentinel lymph node (SLN) staging scheduled, were included in this prospective, Helsinki Declaration compliant, phase I/II trial, 3-group randomized and submitted to an ITS in tumor periphery: G1, Saline; G2, GM-CSF+ETP+(ATH-CV); G3, GM-CSF+ETP+AE (ATH-CV) loaded. At surgery, 26 to 28 days afterwards, SLN was localized by technetium-99, removed and examined: half, pathology and half, flow cytometry immunophenotyping (CD1a+CD83+) and (CD4+CD25+) cells. After surgery, ATH-CV sensitization was tested: intradermal DTH and lab lymphocyte proliferation assay (LPA). Groups were statistically compared by Student t-test (St). Results: a) VSLN pathology was negative for cancer cells in all specimens. b) CD1a+CD83+ cells in VSLN (by 600 CD3+T cells): G1=4.2; G2=11.4; G3=15.4. St: G2 vs G1, p<0.01; G3 vs G2, p<0.05. c) CD4+CD25+ cells in VSLN (% of CD4+ T cells): G1=14.3; G2=4.1; G3=4.3. St: G2 vs G1, p<0.01; G3 vs G2, p>0.05. d) DTH> 5mm (% cases): G1= 0; G2=40; G3=80. e) LPA; (CPM Test/CPM Control); mean (SD): G1=0.98 (0.34); G2=3.66 (0.68); G3=5.17 (0.76). St: G2 vs G1, p<0.02; G3 vs G2, p<0.05. Conclusions: Autologous erythrocytes enhanced the systemic immune responses elicited by ATH-CV acting as carrier of vaccine immunogen from ITS to the immunological protective conditioned VSLN. No significant financial relationships to disclose.
A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint.
Authors: Evan Y. Yu, Michael L. Hancock, Tamas Babicz, Ronald F. Tutrone, Christopher Ng, Laurence H. Belkoff, William J. Aronson, Zsuzsanna Papai, Lajos Geczi, Robert H. Getzenberg
Journal: Journal of Clinical Oncology (2016)

185 Background: Recently approved agents that target the androgen receptor pathway emphasize the importance of the persistent activity of the androgen receptor pathway in castration-resistant prostate cancer (CRPC). This raises the possibility that agents with distinct mechanisms of action may add value. GTx-758 is a selective ERα agonist that can increase SHBG and therefore reduce biologically active testosterone (T) levels. Reported here are the results, including the final primary endpoint analysis, from the 250 mg daily GTx-758 cohort of a phase II clinical trial in men on LHRH agonists that developed CRPC. Methods: This phase II open label trial (G200712, NCT01615120) treated men with high risk nmCRPC or mCRPC with T levels &lt; 50 ng/dL who continued to receive their current form of ADT along with either 125 mg or 250 mg of GTx-758 daily, for at least 90 days. The primary endpoint was the proportion of men with a PSA decline ≥ 50% by day 90, while secondary endpoints included serum total and free T, sex hormone binding globulin (SHBG), bone turnover markers and hot flashes. Results: The 250 mg cohort (n = 39) has completed the time period for assessment of the primary endpoint. Ten of the 39 (26%) subjects exhibited a ≥ 50% decrease in PSA by Day 90, with 11/39 (28%) by Day 120, while 18/39 (46%) had PSA declines of ≥ 30%. Median SHBG levels increased 301% of baseline, confirming the principal mechanism of drug action. While on study, median free T decreases of 44% were observed across all subjects and 20/26 (77%) of the subjects with baseline serum free T levels &gt; 0.7 pg/ml fell below this level. Therefore, 250 mg GTx-758 decreased free testosterone levels in an additive fashion to their existing LHRH therapy. The bone turnover biomarker, C-telopeptide, decreased in 79% of the subjects. 250 mg of GTx-758 has been generally well tolerated with two reported possibly drug related SAEs (VTE and MI). Conclusions: In this phase II trial, 250 mg daily GTx-758 has activity, likely mediated by lowering free T levels in patients with CRPC on LHRH therapy, and may provide amelioration of estrogen deficiency side effects associated with ADT. Clinical trial information: NCT01615120.
TCT-625 The ECG after transcatheter aortic valve implantation determines the need for pacemaker implantation and the required duration of telemetry monitoring
Authors: Stefan Toggweiler, Erik Holy, Richard Kobza, Zaid Sabti, Raluca Suciu, Florim Cuculi, Fabian Nietlispach, Willibald Maier, Peiman Jamshidi, Francesco Maisano, Thomas F. Lüscher, Ronald K. Binder
Journal: Journal of the American College of Cardiology (2015)
Gastrointestinal Lymphorrhea Diagnosed by Exercise Lymphoscintigraphy
Authors: Ana Barić, Vinko Marković, Adela Arapović, Sandra Prgomet, Marijan Saraga
Journal: Clinical Nuclear Medicine (2016)

Lymphoscintigraphy is not considered as a first line diagnostic procedure in abdominal or thoracic lymphorrhea of various origin. We report a patient with lymphangiectasia in whom posttraumatic lymphorrhea was diagnosed by lymphoscintigraphy only after third attempt when we applied pushups exercise with the aim to raise venous pressure and thus provoke lymph backflow in ductus thoracicus and enteric lymphytics. Lymphorrhea was clearly visible in colon ascendens and colon transversum on 9h planar scintigram. We propose exercise lymphoscintigraphy with exercise tailored to individual patient's possibility before each lymphoscintigram to enhance lymphorrhea detection in patients with suspected lymph leakage.
Pleiotropic Role of GSK3 Kinase in Myeloma Cell Biology.
Authors: Francesco A. Piazza, Carmela Gurrieri, Gino Chioetto, Luca Bonanni, Barbara Montini, Samuela Carraro, Anna Cabrelle, Renato Zambello, Livio Trentin, Fausto Adami, Gianpietro Semenzato
Journal: Blood (2006)
Significant Increases in EpiPen Price
Authors: Jeff Lyon
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-284 Comparison of Visual Assessment of Coronary Stenosis with Independent Quantitative Coronary Angiography: Findings from the PROMISE Trial (PROspective Multicenter Imaging Study for Evaluation of chest pain)
Authors: Rohan Shah, William S. Jones, Louis P. Kohl, Udo Hoffmann, Pamela S. Douglas, Eric Yow, Kerry L. Lee, Christopher B. Fordyce, Daniel B. Mark, Alicia L. Lowe, Andrzej S. Kosinski, Manesh Patel
Journal: Journal of the American College of Cardiology (2015)
Coordinate Regulation of NF-κB Subunit Expression in EBV Negative, but Not EBV Positive, Pediatric Hodgkin’s Lymphoma
Authors: Terzah M. Horton, Andrea N Sheehan, Dolores Lopez-Terrada, Robert Edward Hutchison, Sonia Narendra, Meghan A. Higman, Meng-Fen Wu, Hao Liu
Journal: Blood (2008)
Genetic Determinants of Response and Survival in Momelotinib Treated Myelofibrosis Patients
Authors: Animesh Pardanani, Ramy A. Abdelrahman, Christy Finke, Terra L Lasho, Kebede Begna, Aref Al-Kali, William J. Hogan, Mark R. Litzow, Curtis A. Hanson, Rhett Ketterling, Ayalew Tefferi
Journal: Blood (2014)
TCT-347 The impact of post-dilatation on stent expansion and eccentricity using the novel balloon delivery system for the self-apposing coronary artery stent; a detailed Optical Coherence Tomography analysis
Authors: Huangling Lu, Alexander J. IJsselmuiden, Maik J. Grundeken, Martina Nassif, Arie G. de Vries, Auke Weevers, Martijn Scholte, René Spaargaren, Joanna J. Wykrzykowska, Jan G. Tijssen, Robbert J. de Winter, Karel T. Koch
Journal: Journal of the American College of Cardiology (2015)
Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01).
Authors: Jonathan W. Friedberg, Philip Cohen, Bruce D. Cheson, K. Sue Robinson, Andres Forero-Torres, Luis Fayad, Ann S. La Casce, Alberto Bessudo, Elber S. Camacho, Michael E. Williams, Richard H. van der Jagt, Jennifer Oliver, Ely Benaim
Journal: Blood (2005)
Mechanical Stress Conditioning and Electrical Stimulation Promote Contractility and Force Maturation of Induced Pluripotent Stem Cell-Derived Human Cardiac Tissue
Authors: Jia-Ling Ruan, Nathaniel L. Tulloch, Maria V. Razumova, Mark Saiget, Veronica Muskheli, Lil Pabon, Hans Reinecke, Michael Regnier, Charles E. Murry
Journal: Circulation (2016)

Tissue engineering enables the generation of functional human cardiac tissue with cells derived in vitro in combination with biocompatible materials. Human-induced pluripotent stem cell-derived cardiomyocytes provide a cell source for cardiac tissue engineering; however, their immaturity limits their potential applications. Here we sought to study the effect of mechanical conditioning and electric pacing on the maturation of human-induced pluripotent stem cell-derived cardiac tissues.Cardiomyocytes derived from human-induced pluripotent stem cells were used to generate collagen-based bioengineered human cardiac tissue. Engineered tissue constructs were subjected to different mechanical stress and electric pacing conditions.The engineered human myocardium exhibits Frank-Starling-type force-length relationships. After 2 weeks of static stress conditioning, the engineered myocardium demonstrated increases in contractility (0.63±0.10 mN/mm2 vs 0.055±0.009 mN/mm2 for no stress), tensile stiffness, construct alignment, and cell size. Stress conditioning also increased SERCA2 (Sarco/Endoplasmic Reticulum Calcium ATPase 2) expression, which correlated with a less negative force-frequency relationship. When electric pacing was combined with static stress conditioning, the tissues showed an additional increase in force production (1.34±0.19 mN/mm2), with no change in construct alignment or cell size, suggesting maturation of excitation-contraction coupling. Supporting this notion, we found expression of RYR2 (Ryanodine Receptor 2) and SERCA2 further increased by combined static stress and electric stimulation.These studies demonstrate that electric pacing and mechanical stimulation promote maturation of the structural, mechanical, and force generation properties of human-induced pluripotent stem cell-derived cardiac tissues.
GW27-e0118 The prevalence of coronary anomalies in a single center of Korea: origination, course, and termination anomalies of aberrant coronary arteries detected by ECG-gated cardiac MDCT
Authors: June Namgung, Hae Won Jung, Jae-Jin Kwak, Sung Uk Kwon, Joon Hyung Doh, Sung Yun Lee, Won Ro Lee
Journal: Journal of the American College of Cardiology (2016)
Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes
Authors: Sriram Sundaravel, Tushar D. Bhagat, Carolina Schinke, David Ebenezer, Hui Liu, Yiting Yu, Andrea Pellagatti, Jacqueline Boultwood, Vijay Yajnik, Andrew Artz, Amit Verma, Amittha Wickrema
Journal: Blood (2012)
TCT-665 Safety and Efficacy of Second Generation Self Expanding Portico® Valve System for the Treatment of Failed Aortic Bioprosthesis: Results from an International Multicenter Valve-in-Valve Registry
Authors: Sami Alnasser, Danny Dvir, Thomas Walther, Won-Keun Kim, Francesco Bedogni, Luca Testa, Hafid Amrane, A.J. van Boven, Marc Pelletier, Josep Rodes-Cabau, Maria Del Trigo, Nicolas M. Van Mieghem, Peter De Jaegere, Christian Frerker, Ganesh Manoharan, Mark S. Spence, Stephen G. Worthley, Anita W. Asgar, Reda Ibrahim, Carmelo Sgroi, Gerlando Pilato, Dion Stub, Webb John, Asim Cheema
Journal: Journal of the American College of Cardiology (2015)
The Interplay Between Microrna-223 and E2F1 Regulates Cell Cycle Control During Granulopoiesis.
Authors: John Anto Pulikkan, Viola Dengler, Philomina Sona Peramangalam, Abdul A. Peer Zada, Carsten Müller tidow, Stefan K Bohlander, Daniel G. Tenen, Gerhard Behre
Journal: Blood (2009)
Mass Cytometry Analysis Dissects CRLF2-Driven Signaling Pathways in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Authors: Jolanda Sarno, Kara L. Davis, Angela Maria Savino, Cristina Bugarin, Stefania Pinto, Chiara Buracchi, Astraea Jager, Chiara Palmi, Ruth C Barber, Daniela Silvestri, Gianni Cazzaniga, Martin J.S. Dyer, Andrea Biondi, Garry P. Nolan, Giuseppe Gaipa
Journal: Blood (2015)
TCT-160 A Novel Thin Strut (100 μm) Sirolimus-Eluting Bioresorbable Scaffold With Hybrid Cell Design: Preclinical Evaluation In Porcine Coronary Arteries
Authors: Pawel Gasior, Yanping Cheng, Lijie Wang, Gaoke Feng, Gerard B. Conditt, Jenn McGregor, Frank D. Kolodgie, Renu Virmani, Juan Granada, Greg L. Kaluza
Journal: Journal of the American College of Cardiology (2015)
GW27-e1047 Clinical Significance of Respiratory Compensation During Exercise Testing in Cardiac Patients
Authors: Rujie Qin, Osamu Nagayama, Yuta Takayanagi, Arisa Nagamine, Longmei Wu, Jo Kato, Isao Nishi, Yuko Katoh, Takeshi Yamashita, Akira Koike, Kazutaka Aonuma
Journal: Journal of the American College of Cardiology (2016)
One Half of Patients with Waldenström Macroglobulinemia Have Large Deletions of Chromosome 6q.
Authors: Scott Van Wier, Wee-Joo Chng, Greg Ahmann, Rachel Rempel, Azzah Al Masri, Morie Gertz, Angela Dispenzieri, Philip Greipp, Roelandt F.J. Schop, Rafael Fonseca
Journal: Blood (2005)
A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1
Authors: Sonja Burgstaller, Richard Greil, Reinhard Stauder, Sigrid Machherndl-Spandl, Michael Pfeilstöcker, Thomas Kuehr, Alois Lang, Beate Mayrbaeurl, Andreas L. Petzer, Peter Valent, Josef Thaler
Journal: Blood (2014)
Is adjuvant systemic chemotherapy after resection of metastases from colorectal cancer suitable?
Authors: M. A. Pantaleo, G. Brandi, E. Derenzini, S. Fanello, M. Di Marco, M. Di Battista, E. Nobili, G. Biasco
Journal: Journal of Clinical Oncology (2004)

3654 Background: In patients affected by metastatic colorectal cancer surgical resection of metastases improves the overall survival (OS) and represents the only potentially curative therapy in spite of the high 2 years-recurrence rate of disease. Adjuvant chemotherapy via hepatic arterial infusion (HAI) after resection of liver metastases has shown its efficacy in terms of disease free survival (DFS) but not for OS. On the contrary, the role of adjuvant systemic chemotherapy after metastases resection (ASCMR) was rarely investigated in randomised trials. This retrospective analysis has considered the role of ASCMR on DFS in patients submitted to radical resection of lung or liver metastases (synchronous or metachronous at first recurrence) from colorectal cancer between June 1996 and January 2003 in our centre. Methods: 48 patients were eligible; 32 received ASCMR (M19; F 13) and 16 did not receive any therapy (M 8; F 8). ASCMR used regimens were: 9 pts Mayo clinic (mean number of infusion 6,2 range 3–12); 10 pts Folfox-4 (6,2 range 3–11); 4 pts Folfiri (6,5 range 5–9); 9 pts De Gramont (6,5 range 6–10).The characteristics of patients and lesions are reported in Tab 1 Results: Results are reported in Tab 1 Conclusions: The features of the disease in the two groups of patients (treated with ASCMR and not) are not different. DFS is statistically higher for patients submitted to ASCMR (in particular for lung metastases). In conclusions the adjuvant systemic chemotherapy after resection of metastases from colorectal cancer could prolong DFS, but large prospective studies are needed to define overall survival. No significant financial relationships to disclose.
TCT-328 In Vivo Calculation of Endothelial Shear Stress Using Coronary Computed Tomography Angiography: Comparison with Invasive Coronary Angiography
Authors: Saeb R. Lamooki, Takashi Muramatsu, Wenjie Yang, Yingguang Li, Yasuomi Nagahara, Pieter Kitslaar, Lili Liu, Masayoshi Sarai, Yukio Ozaki, Fuhua Yan, Johan H. Reiber, Shengxian Tu
Journal: Journal of the American College of Cardiology (2015)
Face Mask vs Helmet for Noninvasive Ventilation—Reply
Authors: Bhakti K. Patel, Jesse B. Hall, John P. Kress
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II study of ADI-PEG 20 in patients with relapsed sensitive or refractory small cell lung cancer.
Authors: Sinhan Tran, Neal Ready, Lee M. Krug, Maria Catherine Pietanza, Achim A Jungbluth, Linda S. Pan, Ralph Rudolph Venhaus, Eric W. Hoffman, Ann-Marie Peters, Karen Dukelow, John S. Bomalaski, Bor-Wen Wu, Lloyd J. Old
Journal: Journal of Clinical Oncology (2012)

e17558 Background: Small cell lung cancer (SCLC) is a rapidly progressing malignancy. The majority of patients show relapse after initial therapy. Second-line chemotherapy has limited activity, and alternative therapies are desperately needed. ADI-PEG 20 is pegylated recombinant arginine deiminase which degrades arginine, resulting in growth inhibition of SCLC tumor cells deficient in argininosuccinate synthetase (ASS) in xenografts and in vitro, and induction of sensitivity to cell autophagy. Based on ASS deficiency identified in ~50% of human SCLC, a phase II trial in patients with relapsed SCLC was initiated. Methods: This is an open label, multicenter, phase II study of ADI-PEG 20 in subjects with relapsed SCLC. The primary objective is to determine overall response rate according to RECIST. Secondary objectives are to measure safety, overall survival, pharmacodynamics, and immunogenicity. Patients with histologically documented SCLC, measurable disease, and ASS negative (by immunohistochemistry) or weakly positive (&lt; 5%) tumor are eligible. Patients with severe comorbidities, metastatic disease of the central nervous system, prior treatment with 3 or more lines of chemotherapy, and known allergy to pegylated products are excluded. Patients are enrolled in either Cohort 1 (Sensitive disease—response to first-line therapy maintained ≥ 90 days) or Cohort 2 (Refractory disease—no response to first-line therapy or progression within 90 days, or progression after 2 lines of therapy). All patients receive weekly intramuscular injections of ADI-PEG 20 at a dose of 320 IU/m 2 (36.8 mg/m 2 ) until disease progression. The two cohorts will be analyzed separately with a two-stage design. For Cohort 1, if 3/15 patients respond, additional 13 patients will be accrued to the second stage. For Cohort 2, if 1/9 patients responds, additional 8 patients will be accrued to the second stage. Results: Cohort 1 has enrolled 2 of planned 15 patients and Cohort 2 has enrolled 7 of 9 planned patients. Conclusions: Will be published when study is complete.